AIG Hospitals to Launch ₹800 Crore Oncology Centre with South-East Asia’s First Dynamic ARC Proton Therapy

Qiagen Secures FDA Clearance for QIAstat-Dx Gastrointestinal Panel

Ovation.io Launches Groundbreaking GLP-1 Research Dataset to Advance Precision Medicine

Kotak Invests ₹940 Crore in Neuberg Diagnostics to Drive Expansion and IPO Preparation

NICE Recommends Olaparib for BRCA-Mutated Advanced Breast Cancer

SOPHiA GENETICS and Platomics Collaborate to Streamline IVDR Compliance for Clinical Labs

India Unveils Genome Sequencing Data of 10,000 Individuals: A Milestone in Biotechnology Research

Ambry Genetics Advances BRCA2 Variant Classification with CRISPR-Based Study Published in *Nature*

Geneoscopy Secures $105M Series C Funding to Advance Colorectal Cancer Screening

Vertex and Orna Partner to Develop In Vivo Gene Therapies for Blood Disorders

FDA Grants Priority Review to Dizal’s Sunvozertinib for EGFR Exon20ins NSCLC

MD Anderson and Myriad Genetics Forge Strategic Alliance to Advance MRD Testing in Cancer Care

Pillar Biosciences Partners with MSK to Enhance Precision Oncology with OncoKB™ Integration

CytoMed and SunAct Partner to Advance Allogeneic Gamma Delta T Cell Therapy in India

China’s NMPA Approves Astellas’ Zolbetuximab for Advanced Gastric and GEJ Cancer

Home
/
update
/
details

Celemics and Strand Life Sciences Strengthen Partnership for Enhanced NGS Analysis

NextEdge Admin

25 Oct 2024

2 min 20 sec

Strand Life Sciences,partnership,diagnostics,genomics

Celemics and Strand Life Sciences are excited to highlight their strategic collaboration aimed at improving next-generation sequencing (NGS) analysis through an integrated, sample-to-report platform. Together, they deliver clinical-grade genomics reports with assay-specific variant filters, ensuring seamless and efficient workflows for customers across Europe, Asia, and North America.

The partnership combines Celemics’ NGS target enrichment kits and bioinformatics pipeline with Strand’s StrandOmics tertiary analysis platform, ensuring clinical data compliance and secure data residency. As part of its global expansion, Celemics recently opened U.S. offices to better serve growing markets, while Strand continues to support North American clients with advanced genomic solutions.

Over the past 2.5 years, Strand has analyzed various clinical cases for Celemics, leveraging whole exome sequencing for rare diseases and panel-based tests, such as the Hereditary Cancer and OncoRisk Tests. With a three-day turnaround, Strand’s scientists have expertly reviewed over 30,000 variants, providing valuable variant-phenotype associations, even in cases with limited medical data.

Dr. Hyoki Kim, Co-Founder and CEO of Celemics, expressed enthusiasm for the partnership, noting the value of Strand’s expertise in accelerating market integration. Strand CEO Dr. Ramesh Hariharan emphasized their shared goal of expanding NGS-based diagnostics in cancer, rare diseases, and inherited disorders.

Founded in 2010, Celemics specializes in developing reagents and panels for oncology, rare diseases, and biopharma applications. Strand Life Sciences, established in 2000, integrates multiomics research with advanced bioinformatics to offer comprehensive diagnostics and interpretation services globally.